UP - logo
E-resources
Full text
Peer reviewed
  • A comparative study of peri...
    Lloyd, Paul; Hong, Anne; Furrer, Marc A.; Lee, Elaine W. Y.; Dev, Harveer S.; Coret, Maurice H.; Adshead, James M.; Baldwin, Peter; Knight, Richard; Shamash, Jonathan; Alifrangis, Constantine; Stoneham, Sara; Mazhar, Danish; Wong, Han; Warren, Anne; Tran, Ben; Lawrentschuk, Nathan; Neal, David E.; Thomas, Benjamin C.

    World journal of urology, 2022/1, Volume: 40, Issue: 1
    Journal Article

    Purpose To describe and compare differences in peri-operative outcomes of robot-assisted (RA-RPLND) and open (O-RPLND) retroperitoneal lymph node dissection performed by a single surgeon where chemotherapy is the standard initial treatment for Stage 2 or greater non-seminomatous germ cell tumour. Methods Review of a prospective database of all RA-RPLNDs (28 patients) and O-RPLNDs (72 patients) performed by a single surgeon from 2014 to 2020. Peri-operative outcomes were compared for patients having RA-RPLND to all O-RPLNDs and a matched cohort of patients having O-RPLND (20 patients). Further comparison was performed between all patients in the RA-RPLND group (21 patients) and matched O-RPLND group (18 patients) who had previous chemotherapy. RA-RPLND was performed for patients suitable for a unilateral template dissection. O-RPLND was performed prior to the introduction of RA-RPLND and for patients not suitable for RA-RPLND after its introduction. Results RA-RPLND showed improved peri-operative outcomes compared to the matched cohort of O-RPLND—median blood loss (50 versus 400 ml, p  < 0.00001), operative duration (150 versus 195 min, p  = 0.023) length-of-stay (1 versus 5 days, p  < 0.00001) and anejaculation (0 versus 4, p  = 0.0249). There was no statistical difference in complication rates. RA-RPLND had lower median lymph node yields although not significant (9 versus 13, p  = 0.070). These improved peri-operative outcomes were also seen in the post-chemotherapy RA-RPLND versus O-RPLND analysis. There were no tumour recurrences seen in either group with median follow-up of 36 months and 60 months, respectively. Conclusions Post-chemotherapy RA-RPLND may have decreased blood loss, operative duration, hospital length-of-stay and anejaculation rates in selected cases and should, therefore, be considered in selected patients. Differences in oncological outcomes require longer term follow-up.